meropenem was calculated as the number of patients who experienced at least one toxicity/AE of a certain category as a percentage of the total number of patients.Between July 2004 and May 2008, a total of 212 patients were screened for HER2 expression and eligibility criteria at nine The expression of the growth factor receptors HER2 has been studied in different tumour types leading to the standard therapeutic use in breast cancer. Recently trastuzumab in combination with chemotherapy was considered as a new standard option for patients with HER2-positive advanced gastric or gastro–oesophageal junction cancer.In other cancers drugs such as trastuzumab and lapatinib are under investigation.

There are data of HER2 expression in up to 45% of patients with pancreatic cancer in L-Shikimic acid mainly small cohorts Therefore, this study was designed to investigate the combination of trastuzumab and capecitabine as palliative first-line therapy in patients with metastatic pancreatic cancer. Beside the report by Yamanaka et al, there are two reports by Safran et al who first screened 154 patients with pancreatic cancer and showed HER2 overexpression in 21% and 16% of patients, Toxicity was evaluated according to NCI/CTC version 3.0 of 12 December 2003.Sample size calculation was based on the primary endpoint PFS rate 12 weeks after the start of treatment. The number of patients to be included was determined by the two-stage design according to Simon (1989) and was based on the following considerations. After monotherapy with capecitabine, median PFS time is 2.8 months (Cartwright et al, 2002). On the basis of these results, treatment with trastuzumab and capecitabine is considered to be not sufficiently active if the PFS rate 12 weeks after the start of treatment is 50% or lower. Treatment with trastuzumab and capecitabine is considered to be promising for further evaluation if the PFS rate 12 weeks purchase Dienogest after start of treatment is 70% or higher.

In a first step, 23 patients should be included and treated in the study. If 12 or less of these 23 patients were alive and free of PD after 12 weeks, the study should be stopped and the treatment considered ineffective in this group of patients. If at least 13 patients were alive and free of progression after 12 weeks of treatment, recruitment should be continued until 37 patients were included. If 24 or more of these 37 patients were alive and free of progression after 12 weeks, treatment should be considered as promising and should be order Dienogest studied further.the combination chemotherapy with trastuzumab and capecitabine does not result in improved PFS and OS compared with historical gemcitabine or capecitabine alone.

According to these results we do not recommend further evaluation of anti-HER2 treatment in patients with metastatic pancreatic cancer. Microtubules play a fundamental role in diverse cellular functions (cell division, growth, motility) through a very complex order Dienogest dynamic process of polymerization and depolymerization. Hence, they have emerged as an important target for anticancer drugs. The success of the treatments with taxanes in breast cancer and in other tumor types has led to the development of new microtubule-stabilizing agents (MTSAs) as antineoplastic drugs.